1/17
Vocabulary flashcards detailing pharmacology, indications, contraindications, precautions, dosing guidelines, and clinical consultation rules for droperidol according to Queensland Ambulance Service clinical practice guidelines.
Pharmacology
An antipsychotic medication from the butyrophenone group that produces sedation.
Drug class
Antipsychotic
Metabolism
Hepatic metabolism with biliary and renal excretion as inactive metabolites.
Indications
Acute behavioural disturbance meeting all of the following:
Unresponsive to de-escalation strategies
SAT Score >2
Requiring emergency sedation to prevent harm to themselves or others.
Precautions
Hypoperfused state
Concurrent use of CNS depressants.
Side effects
Vasodilation/hypotension
Extrapyramidal effects (such as rare dystonic reactions).
Presentation
Vial of 10mg/2ml droperidol
Pharmacokinetics
Onset: 5-15 minutes
Duration: 4-6 hours
Half-life N/A
Contraindications
Absolute:
Allergy AND/OR Adverse Drug Reaction, known Lewy Body Dementia (LBD), suspected or confirmed Parkinson's disease, previous dystonic reaction to droperidol, and patients less than 8years of age.
Droperidol relative contraindications
Situations requiring QAS Clinical Consultation & Advice Line approval: suspected sepsis, or a patient being physically restrained with no CCP on scene.
Droperidol drug schedule and administration routes
Schedule S4 (Restricted drugs), authorized for intramuscular injection (IM) and intravenous injection (IV) by ACP2 and CCP officers.
Adult droperidol dosage (16years to <65years)
10mg IM or IV; may be repeated once at 15minutes to a total maximum dose of 20mg.
Elderly droperidol dosage (≥65years)
5mg IM or IV; may be repeated once at 15minutes to a total maximum dose of 10mg.
Adolescent droperidol dosage (13−15years)
0.1−0.2mg/kg IM or IV with a single maximum dose of 10mg; may be repeated once at 15minutes to a total maximum dose of 20mg.
Paediatric droperidol dosage (8−12years)
0.1−0.2mg/kg IM or IV with a single maximum dose of 10mg; may be repeated once at 15minutes to a total maximum dose of 20mg (mandatory consultation and approval required in all situations).
Clinical consultation requirements for droperidol administration
Mandatory approval via the QAS Clinical Consultation and Advice Line is required for ACP2 officers treating patients ≥65years OR 13−15years, and for CCP officers treating patients 13−15years.
Droperidol use following olanzapine administration
May be considered for patients who present with increased agitation (SAT score of +2 or +3) after receiving olanzapine.
ACP2 droperidol second dose escalation protocol
Where a second dose of droperidol has been administered by an ACP2, a CCP (where available) must be requested; the responding CCP may be cancelled if the second dose achieves the desired sedation effect.